Cargando…

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]

Detalles Bibliográficos
Autores principales:	Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M.V., Guarneri, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014390/ https://www.ncbi.nlm.nih.gov/pubmed/35398607 http://dx.doi.org/10.1016/j.esmoop.2022.100472

Ejemplares similares

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
por: Miglietta, F., et al.
Publicado: (2022)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
por: Guarneri, V., et al.
Publicado: (2022)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]
por: Cantini, L., et al.
Publicado: (2022)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
por: Peleg Hasson, S., et al.
Publicado: (2021)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)

Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’: [ESMO Open Volume 7, Issue 1, February 2022, 100393]
por: Beechinor, R., et al.
Publicado: (2022)

Erratum to: “Anxiety and neurometabolite levels in the hippocampus and amygdala after prolonged exposure to predator-scent stress”
por: Shevelev, O.B., et al.
Publicado: (2020)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Erratum, Vol. 10, April 26 Release
Publicado: (2013)

Erratum, Vol. 10, April 25 Release
Publicado: (2013)

Erratum, Vol. 12, April 2 Release
Publicado: (2015)

Erratum, Vol. 12, April 30 Release
Publicado: (2015)

Erratum, Vol. 10, April 4 Release
Publicado: (2013)

Erratum, Vol. 16, April 18 Release
Publicado: (2019)

Erratum, Vol. 13, April 28 Release
Publicado: (2017)

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
por: Miglietta, Federica, et al.
Publicado: (2022)

Erratum, Vol. 10, April 11, 2013 Release
Publicado: (2014)

Erratum, Vol. 20, April 13, 2023 Release
Publicado: (2023)

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
por: Ratosa, Ivica, et al.
Publicado: (2022)

Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’: [Annals of Oncology 30 (2019) 1221–1231]
por: Mandelker, D., et al.
Publicado: (2021)

Erratum to ‘COVID-19 vaccine-associated subclinical axillary lymphadenopathy on screening mammogram’ [Academic Radiology Volume 29, Issue 4, April 2022, Pages 501-507]
por: Raj, Sean, et al.
Publicado: (2022)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
por: Griguolo, Gaia, et al.
Publicado: (2022)

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Erratum: SDDF Abstracts 2022
Publicado: (2023)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Erratum: Treatment options for pediatric craniopharyngioma
Publicado: (2016)

In the literature: April 2022
por: Ciardiello, D., et al.
Publicado: (2022)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
por: Lee, R.J., et al.
Publicado: (2021)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Erratum for Euro Surveill. 2022;27(2)
Publicado: (2022)

Erratum for Euro Surveill. 2022;27(22)
Publicado: (2022)

Erratum for Euro Surveill. 2022;27(31)
Publicado: (2022)

Erratum for Euro Surveill. 2022;27(43)
Publicado: (2022)

Erratum for Euro Surveill. 2022;27(39)
Publicado: (2022)

Erratum to: Chordoma: The Quest for Better Treatment Options
por: Heery, Christopher R.
Publicado: (2016)

The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
por: Zarrilli, Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v8mdc1brabufjphh0002gjoji